SSTR2 and nasopharyngeal carcinoma: On the other hand, recent studies have suggested that SSTR2 may be a therapeutic target in nasopharyngeal carcinoma associated with infection by the Epstein–Barr virus [14] and that the increased SSTR2 expression induced by the epidrugs, such as the DNA methyltransferase inhibitor and the histone deacetylase inhibitor, may improve treatment strategies for patients with neuroendocrine tumors [15].